Basic characteristics of the studies included. by Renáta Kiss-Miki (20760127)

Subjects:

PRISMA flowchart of the article selection process. by Renáta Kiss-Miki (20760127)

Subjects:

List_of_studies_identified_31-JAN-2025. by Renáta Kiss-Miki (20760127)

Subjects:

Forest plot showing the mean difference of global IQ level among pediatric brain cancer patients treated with either PT or XRT. by Renáta Kiss-Miki (20760127)

Subjects:

Forest plot showing the ratio of odds of hypothyroidism (=event) among pediatric brain cancer patients treated with either PT or XRT. by Renáta Kiss-Miki (20760127)

Subjects:

Forest plot showing the ratio of odds of acute side effects: nausea (a) and vomiting (b) (=events) among pediatric patients with brain tumors treated with PT or XRT. by Renáta Kiss-Miki (20760127)

Subjects:

Forest plot showing the odds of 5-year overall-survival rate among children with brain tumors treated with either PT or XRT. by Renáta Kiss-Miki (20760127)

Subjects:

Data_table_with_all_identified_articles_31-JAN-2025. by Renáta Kiss-Miki (20760127)

Subjects:

Data_extraction_table_31-JAN-2025. by Renáta Kiss-Miki (20760127)

Subjects:

Forest plot showing the ratio of odds of grade 3 anemia (=event) among pediatric patients with brain tumors treated with either PT or XRT. by Renáta Kiss-Miki (20760127)

Subjects:

Immunogenicity results of different vaccination schemes at different time points. by Rima Moghnieh (679199)

Subjects:

Effectiveness of the available COVID-19 primary and booster vaccination schemes against laboratory-confirmed infections during the different waves. by Rima Moghnieh (679199)

Subjects:

Effectiveness of the available COVID-19 primary and booster vaccination schemes against acute-care hospitalization attributed to laboratory-confirmed infections during the differen... by Rima Moghnieh (679199)

Subjects:

Immunogenicity assessment groups based on the primary and booster vaccination schemes and timeframe from the second or booster dose. by Rima Moghnieh (679199)

Subjects:

Demographic and clinical characteristics of the participants used to estimate effectiveness of the different vaccination schemes during the Omicron BA.4/BA.5 variant wave. by Rima Moghnieh (679199)

Subjects:

Humoral immune responses to SARS-CoV-2 spike protein following various primary vaccination schemes and booster doses with Sinopharm or Pfizer vaccines among COVID-19-naïve particip... by Rima Moghnieh (679199)

Subjects:

Demographic and clinical characteristics of the participants used to estimate effectiveness of the different vaccination schemes during the Alpha variant wave. by Rima Moghnieh (679199)

Subjects:

Demographic and clinical characteristics of the participants used to estimate effectiveness of the different vaccination schemes during the Omicron BA.1/BA.2 variant wave. by Rima Moghnieh (679199)

Subjects:

Fig 4 - by Rima Moghnieh (679199)

Subjects:

Demographic and clinical characteristics of the participants used to estimate effectiveness of the different vaccination schemes during the Delta variant wave. by Rima Moghnieh (679199)

Subjects: